While Pfizer's (PFE) and J&J's (JNJ) bapineuzumab Alzheimer's drug failed in a Phase III...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

While Pfizer's (PFE) and J&J's (JNJ) bapineuzumab Alzheimer's drug failed in a Phase III trial of people who already exhibit symptoms, scientists may yet test it on those at risk of the disease but aren't yet affected. Pfizer and J&J, though, don't yet have plans to assess bapineuzumab for this purpose.